British Patient Capital invests £8.7m in Perspectum’s Series C funding round
Press release
Today British Patient Capital announces that it has invested £8.7m in Oxford-headquartered medical technology business Perspectum as part of its £31m Series C funding round.
The investment has been made via Future Fund: Breakthrough, British Patient Capital’s £375m programme which co-invests with private sector investors in innovative, R&D-intensive UK companies. Other investors in the round include Oppenheimer, HealthQuest Capital and Blue Venture Fund.
Perspectum is a leader in the field of precision health technology, delivering advanced solutions to health care providers. Using deeptech and the latest innovations in medicine, the business empowers patients and clinicians to better understand chronic systemic diseases and cancers, enabling early detection, diagnosis, and targeted treatment.
The Series C investment will support Perspectum’s global rollout and future product development.
Life sciences and deeptech are two bright spots within the UK’s innovation economy, and Perspectum is bringing the two together as they pioneer technological developments that are revolutionising the patient experience. Through our Future Fund: Breakthrough programme, we are excited to work with an industry-leading team at Perspectum and support their global growth ambitions. Catherine Lewis La Torre CEO, British Patient Capital
Further Information
Notes to editors
About British Patient Capital
British Patient Capital Limited is a wholly owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large-scale businesses. Launched in June 2018, British Patient Capital has more than £3bn of assets under management, investing in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up. Find out more about British Patient Capital.
British Business Bank plc and its subsidiary entities are not banking institutions and do not operate as such. They are not authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). A complete legal structure chart for British Business Bank plc and its subsidiaries can be found on the British Business Bank plc website.
British Patient Capital makes commitments and invests on its own behalf and on behalf of third-party investors whose investments British Patient Capital manages.
The transaction described above does not constitute or imply any endorsement, warranty or recommendation by the UK government, the British Business Bank plc, its subsidiaries or any other party of Perspectum or its products or services.
About Perspectum
Perspectum, a global medical technology company with offices in the UK, the US, Portugal and Singapore, delivers leading digital technologies that help clinicians provide better care for patients with chronic metabolic diseases, multi-organ pathology, and cancer. With a strong focus on precision medicine using advanced imaging and genetics, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale. For additional information please visit perspectum.com and LinkedIn.
Quick links
Latest news
-
Read more about British Patient Capital announces $50.8m commitment to Evolution Technology Fund III Press release
25 April 2024 -
Read more about British Patient Capital announces £7m investment in Financial Wellbeing Fintech - Wagestream Press release
17 April 2024 -
Read more about British Patient Capital announces £5.5m commitment to Phagenesis Press release
04 March 2024